Drug for Alzheimer鈥檚 gets regulator鈥檚 nod
Print Edition
A NEW drug for Alzheimer’s treatment to be approved for the first time in 17 years could benefit 500,000 patients initially.
GV-971, developed in China, is a seaweed-based drug, which can improve cognitive ability in people suffering from mild-to-moderate Alzheimer’s by regulating bacteria in the gut.
The National Medical Products Administration has approved sale of the drug, but further research of its pharmacological mechanism, and monitoring of long-term safety and effectiveness is required.
The drug was developed by the Ocean University of China, Shanghai Green Valley Pharmaceutical Company and Shanghai Institute of Materia Medica under Chinese Academy of Sciences.
Lu Songtao, chairman of the Green Valley Pharmaceutical company, said production of the first batch of capsules will begin on November 7.
“We believe we can produce enough drugs for 2 million patients in a year,” Lu said.
The company hopes to begin clinical trials in the US soon, as part of its ambition to promote the drug globally.
Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory, thinking skills, and the ability to carry out simple tasks. There is currently no cure for the condition. Currently, there are about 50 million people suffering from Alzheimer’s disease globally. It is the third biggest health risks for the elderly, following cardiovascular disease and cancer.
In China, 10 million people are living with Alzheimer’s, nearly 20 percent of the world’s total, and the number is expected to rise to 40 million by 2050.
“Before GV-971, there were only five medications, without obvious positive effects. They are just symptomatic treatments, and they can’t delay or prevent progress of the disease,” said Xiao Shifu of the Shanghai Mental Health Center.
Over last two decades, pharmaceutical companies across the world have spent hundreds of billions in search of breakthroughs. But more than 300 drugs failed clinical trials.
In Alzheimer’s patients, excessive amyloid beta proteins clump together to form plagues and tangles which impair brain functions. Scientists have been dedicated to finding ways to eliminate the toxic proteins and invent drugs targeting the brain.
Geng Meiyu from the Shanghai Institute of Materia Medica took an unconventional approach.
“You can’t simply think it’s the problem with the head if you have headache. Likewise, Alzheimer’s is not just a brain problem. Instead, it’s a complicated disease,” Geng said. “You can’t confine yourself to just one aspect.”
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
